A Study of the Natural History of Monoclonal Gammopathy of Undetermined Significance (MGUS) Over Time


About this study

The primary purpose of this study is to evaluate the risk of progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myleoma (MM) and other lymphoproliferative disorders (LPDs), in individuals from high-risk families, through serial monitoring of markers of progression (i.e., M-protein, Free light chain).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Eligible subjects will be those who provided prior consent under protocols 2128-05, 2118-05, 1465-04, and 489-04.

Exclusion Criteria: 

  • Not in one of the above studies or deceased since prior contact.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Celine Vachon, Ph.D.

Closed-enrolling by invitation

What is this? (?)
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Mayo Clinic Footer